Nature Medicine Publ
Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, the Netherlands, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore...
ONWARD versterkt man
ONWARD versterkt management met kernfuncties in Klinische & Regelgevende en Marketingafdelingen
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, Nederland, LAUSANNE, Zwitserland & BOSTON, MA, VS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve therapieën...
ONWARD renforce son
ONWARD renforce son management avec des nominations clés dans le domaine clinique et réglementaire et en marketing
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, Pays-Bas, LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, 06 nov. 2023 (GLOBE NEWSWIRE) -- ONWARD Medical SA (Euronext: ONWD), société de technologie médicale créant des thérapies innovantes...
ONWARD verstärkt Füh
ONWARD verstärkt Führungsteam auf Schlüsselpositionen in den Bereichen Clinical & Regulatory sowie Marketing
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, Niederlande, LAUSANNE, Schweiz und BOSTON, MA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Das Medizintechnikunternehmen ONWARD Medical N.V. (Euronext: ONWD), das innovative Therapien zur...
logo.jpg
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023 07:00 ET | AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...
logo.jpg
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
October 27, 2023 07:00 ET | AC Immune SA
PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the...
logo.jpg
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 05, 2023 07:00 ET | AC Immune SA
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage...
logo.jpg
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023 07:00 ET | AC Immune SA
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat...
RaceTrac Logo w tagline.png
RaceTrac’s Run For Research 5K Returns to Truist Park September 16
August 03, 2023 14:00 ET | Racetrac, Inc.
ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- According to The Michael J. Fox Foundation for Parkinson’s Research (MJFF), six million people worldwide live with Parkinson’s disease. One million of...
logo.jpg
AC Immune SA Appoints New Chief Medical Officer
July 26, 2023 07:00 ET | AC Immune SA
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:...